Valneva SE reported its condensed consolidated financial results for the first half of 2025, with total revenues reaching €97.6 million, up from €70.8 million in the first half of 2024. Total product sales were €91.0 million, showing a significant increase from €68.3 million in the prior-year period, which was impacted by supply constraints.
IXIARO®/JESPECT® sales increased by 30.6% to €54.7 million, driven by double-digit growth to travelers and the U.S. Department of Defense. DUKORAL® sales grew 16.4% to €17.4 million, supported by supply to Mayotte. IXCHIQ® sales reached €7.5 million, benefiting from vaccine doses supplied to La Réunion during a major chikungunya outbreak.
The company confirmed its 2025 financial guidance, projecting product sales between €170 million and €180 million. Valneva also reported a substantial reduction in net cash used in operating activities, which decreased to €10.9 million from €66.3 million in the first half of 2024, demonstrating improved financial discipline and efficient cost management.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.